Journal article icon

Journal article

Plasma and Intracellular Concentrations of Doxycycline and Azithromycin in Patients with Severe Scrub Typhus

Abstract:
Background/Objectives: Scrub typhus, a life-threatening infection caused by Orientia tsutsugamushi, is treated with doxycycline or azithromycin. In severe disease, combination therapy with azithromycin and doxycycline had better clinical outcomes than either drug alone. However, it is not clear what causes the improved efficacy. To understand the same, we examined the plasma concentrations, intracellular concentrations, and efficacy of doxycycline, azithromycin, and both drugs in combination in 51 patients with severe scrub typhus. Methods: A randomly selected subset of adult (>18 years) participants from the INTREST trial (Clinical Trials Registry–India, number CTRI/2018/08/015159), who had been randomized in a 1:1:1 ratio to receive doxycycline, azithromycin, or both drugs, respectively, were included in this study for comparative drug concentration analysis. Blood samples were collected on days 0, 1, 3, and 7 to monitor bacterial load using quantitative polymerase chain reaction (PCR). Five milliliters of sterile blood were collected 3–10 h after the final dose on day 7 for comparative drug concentration measured using high-resolution multiple reaction monitoring. Data were analyzed in GraphPad Prism v.10.0.3. Results: Fifty-one patients (males, 59%; median age, 52 years) were enrolled. Fifteen, seventeen, and nineteen patients received azithromycin, doxycycline, and both, respectively. Doxycycline achieved a median plasma concentration of 1112 (42.51–5697) ng/mL and was undetectable intracellularly. The intracellular concentration of azithromycin (1127 [16.78–19,250] ng/mL) surpassed its plasma concentration (227.1 [48.78–1022] ng/mL). On day 3, PCR negativity rates were 56.24%, 93.3%, and 94.7% in the doxycycline, azithromycin, and combination groups, respectively. Conclusions: The high plasma concentrations of doxycycline and intracellular accumulation of azithromycin may contribute to improved clinical outcomes when used in combination.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.3390/antibiotics15050450

Authors

More by this author
Role:
Author
ORCID:
0000-0002-2676-4936
More by this author
Role:
Author
ORCID:
0000-0002-8008-1810


More from this funder
Funder identifier:
https://ror.org/04reqzt68
More from this funder
Funder identifier:
https://ror.org/029chgv08


Publisher:
MDPI
Journal:
Antibiotics More from this journal
Volume:
15
Issue:
5
Pages:
450
Article number:
450
Publication date:
2026-04-30
Acceptance date:
2025-12-06
DOI:
EISSN:
2079-6382
ISSN:
2079-6382


Language:
English
Keywords:
Source identifiers:
4040367
Deposit date:
2026-05-13
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP